Recently, a study in Nature also reported a similar observation that anti-PD-L1 or anti-PD1 therapy reduces survival in specific hepatocellular carcinoma patients, probably as a result of abnormal T cell activation caused by ICI-mediated damage to immune surveillance (34). This evidence concerns the gene CD274 and hepatocellular carcinoma.